MxA mRNA Quantification and Disability Progression in Interferon Beta-Treated Multiple Sclerosis Patients
Federico Serana(University of Brescia), Ruggero Capra(Presidio Ospedaliero), Vittorio Martinelli(Vita-Salute San Raffaele University), Leandro Provinciali(Ospedali Riuniti di Ancona), Claudio Gasperini(Nini Hospital), Gıancarlo Comı(Casa di Cura Columbus), Maria Pia Amato(University of Florence), Stefano Sotgiu(Centro Studi GISED), Michele Vecchio(University of Catania), Luisa Imberti(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Cinzia Cordioli(Ospedale Policlinico San Martino), S. Stecchi(Istituto delle Scienze Neurologiche di Bologna), Mauro Zaffaroni(Associazione Italiana Sclerosi Multipla), Maria Rosa Rottoli(Martin University), Angelo Ghezzi
Cited by 15
Related Papers
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study
|The Lancet|2001|1.1k
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines
|The Lancet Neurology|2016|863
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
|Multiple Sclerosis Journal|2018|706